Literature DB >> 17234819

Apolipoprotein A1 is a stronger prognostic marker than are HDL and LDL cholesterol for cardiovascular disease and mortality in elderly men.

Gösta Florvall1, Samar Basu, Anders Larsson.   

Abstract

The aim of this study was to compare apolipoprotein A1 (ApoA1) and B (ApoB) with high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) as markers for cardiovascular mortality and morbidity in elderly men. We analyzed serum ApoA1, ApoB, total cholesterol, HDL-C, and LDL-C in a group of 77-year-old men (n = 785). The results were correlated with data from the Swedish cause of death registry. Receiver-operating characteristic curves showed that, of the studied serum markers, ApoA1 was the best predictor for ischemic heart disease mortality (area under the curve = 0.724, 95% confidence interval, 0.691-0.755). There were also significant correlations between the apolipoproteins and other known risk markers for cardiovascular disease such as triglycerides, high-sensitivity C-reactive protein (hsCRP), and cystatin C. Serum ApoA1 is a better risk marker than are ApoB, ApoB/ApoA1 ratio, HDL-C, and LDL-C for cardiovascular disease and mortality in elderly men.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17234819     DOI: 10.1093/gerona/61.12.1262

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  21 in total

Review 1.  The effect of chronic kidney disease on lipid metabolism.

Authors:  Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-12-05       Impact factor: 2.370

2.  To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?

Authors:  Carl J Lavie; Richard V Milani; James H O'Keefe
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

Review 3.  New frontiers in the treatment of diabetic dyslipidemia.

Authors:  Shu-Yi Wang; Ming-Chia Hsieh; Shih-Te Tu; Chieh-Sen Chuang
Journal:  Rev Diabet Stud       Date:  2013-08-10

4.  Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity.

Authors:  Elizabeth Suchi Chen; Diego Robles Mazzotti; Tatiane Katsue Furuya; Maysa Seabra Cendoroglo; Luiz Roberto Ramos; Lara Quirino Araujo; Rommel Rodriguez Burbano; Marília de Arruda Cardoso Smith
Journal:  Clin Exp Med       Date:  2009-05-01       Impact factor: 3.984

5.  Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

Authors:  John Ford; Matt Lawson; David Fowler; Nobuko Maruyama; Seiji Mito; Koichi Tomiyasu; Shuji Kinoshita; Chisa Suzuki; Atsuhiro Kawaguchi; Patrick Round; Malcolm Boyce; Steve Warrington; Werner Weber; Sander van Deventer; John J P Kastelein
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

6.  The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight.

Authors:  Francine E Garrett-Bakelman; Manjula Darshi; Stefan J Green; Ruben C Gur; Ling Lin; Brandon R Macias; Miles J McKenna; Cem Meydan; Tejaswini Mishra; Jad Nasrini; Brian D Piening; Lindsay F Rizzardi; Kumar Sharma; Jamila H Siamwala; Lynn Taylor; Martha Hotz Vitaterna; Maryam Afkarian; Ebrahim Afshinnekoo; Sara Ahadi; Aditya Ambati; Maneesh Arya; Daniela Bezdan; Colin M Callahan; Songjie Chen; Augustine M K Choi; George E Chlipala; Kévin Contrepois; Marisa Covington; Brian E Crucian; Immaculata De Vivo; David F Dinges; Douglas J Ebert; Jason I Feinberg; Jorge A Gandara; Kerry A George; John Goutsias; George S Grills; Alan R Hargens; Martina Heer; Ryan P Hillary; Andrew N Hoofnagle; Vivian Y H Hook; Garrett Jenkinson; Peng Jiang; Ali Keshavarzian; Steven S Laurie; Brittany Lee-McMullen; Sarah B Lumpkins; Matthew MacKay; Mark G Maienschein-Cline; Ari M Melnick; Tyler M Moore; Kiichi Nakahira; Hemal H Patel; Robert Pietrzyk; Varsha Rao; Rintaro Saito; Denis N Salins; Jan M Schilling; Dorothy D Sears; Caroline K Sheridan; Michael B Stenger; Rakel Tryggvadottir; Alexander E Urban; Tomas Vaisar; Benjamin Van Espen; Jing Zhang; Michael G Ziegler; Sara R Zwart; John B Charles; Craig E Kundrot; Graham B I Scott; Susan M Bailey; Mathias Basner; Andrew P Feinberg; Stuart M C Lee; Christopher E Mason; Emmanuel Mignot; Brinda K Rana; Scott M Smith; Michael P Snyder; Fred W Turek
Journal:  Science       Date:  2019-04-12       Impact factor: 47.728

Review 7.  Pleiotropic effects of pitavastatin.

Authors:  Jean Davignon
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

8.  The association between obesity, cardiometabolic disease biomarkers, and innate immunity-related inflammation in Canadian adults.

Authors:  Laura A Da Costa; Paul Arora; Bibiana García-Bailo; Mohamed Karmali; Ahmed El-Sohemy; Alaa Badawi
Journal:  Diabetes Metab Syndr Obes       Date:  2012-10-04       Impact factor: 3.168

9.  Simultaneous non-negative matrix factorization for multiple large scale gene expression datasets in toxicology.

Authors:  Clare M Lee; Manikhandan A V Mudaliar; D R Haggart; C Roland Wolf; Gino Miele; J Keith Vass; Desmond J Higham; Daniel Crowther
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

10.  ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity.

Authors:  Min Lu; Qun Lu; Yong Zhang; Gang Tian
Journal:  J Biomed Res       Date:  2011-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.